Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Sanofi SA    SNY

Delayed Quote. Delayed  - 02/08 04:02:01 pm
39.21 USD   -1.53%
10:16a UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's
07:32a SANOFI : Pasteur to leverage its strong vaccine legacy in hunt for z..
07:31a SANOFI : Appoints muzammil mansuri to executive committee and execut..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Sanofi SA
Engages in the research, production and distribution of pharmaceutical products

Sanofi engages in the research, production and distribution of pharmaceutical products.

It operates through the following segments: Pharmaceuticals, Human Vaccines, Animal Health, and Others.

The Pharmaceuticals segment includes research, development, production and sales activities relating to pharmaceutical products, including prescription, consumer health care, and generic products.

This segment also includes equity affiliates and joint ventures with pharmaceutical business activities.

The Human Vaccines segment includes research, development, production and marketing of vaccines.

The Animal Health segment comprises the research, development, production and marketing activities for Merial, which offers a range of medicines and vaccines for a wide variety of animal species.

The Others segment includes all activities that do not qualify as reportable segments under IFRS 8 “Operating Segments”; it also includes the effects of retained commitments in respect of divested businesses.

The company was founded in 1994 and is headquartered in Paris, France.

Number of employees : 113 496 persons.
Sales per Businesses
20132014Delta
USD (in Million)%USD (in Million)%
Pharmaceuticals36,24782.7%36,62882.1% +1.04%
Vaccines4,94311.3%5,25111.8% +5.87%
Animal Health2,6406%2,7436.1% +3.74%
Sales per Regions
20132014Delta
USD (in Million)%USD (in Million)%
Other Countries15,21934.7%15,13333.9% -0.56%
United States13,87831.7%14,98333.6% +7.38%
Europe10,55224.1%10,48123.5% -0.68%
France3,4207.8%3,2697.3% -4.62%
North America762.191.7%755.811.7% -0.84%
Managers
NameAgeSinceTitle
Olivier Brandicourt MD, PhD602015Chief Executive Officer
Serge Weinberg652009Chairman
Jérôme Contamine592009Chief Financial Officer & EVP-Finance
Elias E. Zerhouni, MD652011President-Global Research & Development
Robert Castaigne, PhD702000Independent Director
Jean-René Fourtou772004Independent Director
Claudie Haigneré MD, PhD592008Independent Director
Uwe Bicker MD, PhD712008Independent Director
Carole Piwnica582010Independent Director
Suet-Fern Lee582011Independent Director
Shareholders
NameEquities%
Dodge & Cox 49,859,813 1.91%
Barrow, Hanley, Mewhinney & Strauss LLC 29,489,368 1.13%
Franklin Advisers, Inc. 19,056,707 0.73%
Fisher Asset Management LLC 13,416,220 0.51%
Fidelity Management & Research Co. 11,906,352 0.46%
Hotchkis & Wiley Capital Management LLC 9,035,695 0.35%
Invesco Advisers, Inc. 6,967,225 0.27%
Harris Associates LP 5,912,950 0.23%
Berkshire Hathaway, Inc. (Investment Management) 3,905,875 0.15%
Delaware Management Business Trust 3,467,331 0.13%
Holdings
NameEquities%Valuation
Regeneron Pharmaceuticals Inc (REGN) 23,192,50822.7%12,590,516,818 USD
Alnylam Pharmaceuticals, Inc. (ALNY) 10,256,63312.1%965,559,431 USD
Aventis Pharma Limited (AVPH) 13,909,58760.4%916,232,424 USD
Zentiva SA (ROSCD) 312,341,64974.9%153,522,167 USD
Nichi-iko Pharmaceutical Co., Ltd. (4541) 2,846,0004.69%68,618,426 USD
Myokardia Inc (MYOK) 3,218,89911.9%47,189,059 USD
Merrimack Pharmaceuticals Inc (MACK) 3,074,7182.66%24,290,272 USD
Immune Design Corp (IMDZ) 917,4294.55%18,421,974 USD
SCYNEXIS Inc (SCYX) 1,677,05712.1%10,414,524 USD
Proteome Sciences plc (PRM) 38,0000.017%8,821 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals
Growth (Revenue) Profitability
JOHNSON & JOHNSON
ROCHE HOLDING LTD..
NOVARTIS AG
PFIZER INC.
MERCK & CO., INC.
ALLERGAN PLC
SANOFI
NOVO NORDISK A/S
BRISTOL-MYERS SQU..
GLAXOSMITHKLINE P..
BAYER AG
ELI LILLY AND CO
ASTRAZENECA PLC
TEVA PHARMACEUTIC..
ABBOTT LABORATORI..
TAKEDA PHARMACEUT..
VALEANT PHARMACEU..
SHIRE PLC
ASTELLAS PHARMA I..
MYLAN NV
Sector Pharmaceuticals
Sanofi SA : Connections
Pres héSam
Sanofi-Aventis Europe SAS
Sanofi-Aventis Participations SA
Aventis Foundation
AXA Asia SAS
Academie des Sports
Piasa Holding
i2O Water Ltd.
Sanofi Pasteur Holding SA
Sanofi Pasteur Holding & Merial Ltd.
Montres CORUM Sàrl
La Campus Condorcet
Sanofi-Aventis U.S. LLC
Académie des Sciences et Technologies
Ruprecht-Karls-Universität Heidelberg
Council on Foreign Relations, Inc.
Elevance Renewable Sciences, Inc.
Research!America
King Abdullah University of Science & Technology
Paris Bar Association
Warp Drive Bio LLC
National Heritage Board
Académie Nationale de Médecine
Singapore Bar
National Academy of Engineering
Fondations René Lacoste
Institute of Medicine
Fondation Lacoste
The Johns Hopkins University
Académie des Technologies
Financières SASA
Academie de l'air et de l'espace
Financière Piasa
Philipps University of Marburg
Weinberg Capital Partners SAS
Alliance Automotive Group SAS
Bordeaux University Foundation
Naxos UK Ltd.
Madrigall SA
Pharmaceutical Research & Manufacturers of America
Big Red, Inc.
RecyCoal Ltd.
Asian Civilisations Museum
Select Music & Video Distribution Ltd.
Piasa SA
New York State Bar Association
The Children's Aid Society, Inc.
NAXOS Capital Managers SARL
Rickmers Trust Management Pte Ltd.
Stamford Law Corp.
Universcience.fr
International Federation of Pharmaceutical Manufacturers A
Nanyang Technological University
Fondation de France
Stamford Corporate Services Pte Ltd.
Fondation C.Génial
AXA Group Solutions
L'Oréal Corporate Foundation
World Justice Project
École Normale Supérieure
International Bar Association
Company contact information
Sanofi
54, rue La Boétie
Paris, Ile-de-France 75008

Phone : +33.1.53.77.40.00
Fax : +33.1.53.77.44.63
Web : www.sanofi.com
© 2016 People , Fundamentals and Ownership